SCHEMBL2866530

SCHEMBL2866530

CC1CCC(C(=O)O)=C1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.39
KMT2A Q03164 1/20 0.33
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
CA4 P22748 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1817189 0.86 KMT2A (0.40) HCAR2KMT2ACA1CA2CA4
SCHEMBL344894 0.75
SCHEMBL191061 0.74 HCAR2 (0.38) HCAR2
SCHEMBL28461042 0.74 HCAR2 (0.38) HCAR2
SCHEMBL258822 0.74 ALDH1A1 (0.31)
SCHEMBL29131699 0.73 HCAR2 (0.34) HCAR2
SCHEMBL321770 0.71 KDM4E (0.30)
SCHEMBL28835956 0.71 HCAR2 (0.37) HCAR2
SCHEMBL6659836 0.71 ALDH1A1 (0.33) HCAR2KMT2ACA1CA2CA4
SCHEMBL8039515 0.71 GRM5 (0.33) KMT2ACA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4326247-A1 CITRACONIC ACID AND DERIVATIVES THEREOF FOR USE AS A MEDICAMENT Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2024-02-28 EP claimed
CN-117202901-A Use of citraconic acid and its derivatives as medicaments 亥姆霍兹感染研究中心有限公司 2023-12-08 CN claimed
WO-2022223778-A1 CITRACONIC ACID AND DERIVATIVES THEREOF FOR USE AS A MEDICAMENT Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2022-10-27 WO claimed
US-20240368065-A1 CITRACONIC ACID AND DERIVATIVES THEREOF FOR USE AS A MEDICAMENT Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2024-11-07 US disclosed
EP-4326247-A1 CITRACONIC ACID AND DERIVATIVES THEREOF FOR USE AS A MEDICAMENT Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2024-02-28 EP disclosed
CN-117202901-A Use of citraconic acid and its derivatives as medicaments 亥姆霍兹感染研究中心有限公司 2023-12-08 CN disclosed
WO-2022223778-A1 CITRACONIC ACID AND DERIVATIVES THEREOF FOR USE AS A MEDICAMENT Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2022-10-27 WO disclosed
US-20190135774-A1 BIOMOLECULE PROCESSING FROM FIXED BIOLOGICAL SAMPLES CELL DATA SCIENCES, INC. (US) 2019-05-09 US disclosed
WO-2017184984-A1 BIOMOLECULE PROCESSING FROM FIXED BIOLOGICAL SAMPLES CELL DATA SCIENCES, INC. (US) 2017-10-26 WO disclosed
US-20100321863-A1 ACTIVATED CARBON AND PROCESS FOR PRODUCING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-12-23 US disclosed
US-7800886-B2 Electric double layer capacitor SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-21 US disclosed
US-7785495-B2 Activated carbon prepared by carbonizing and activating a calixarene containing dihydroxybenzene rings; especially calcining at 400 degrees C. or less in the presence of an oxidative gas, calcining at 1500 degrees or less in an inactive gas, and then further calcining at 200-1500 degrees in H2O or CO2 SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-08-31 US disclosed
EP-2093191-A1 ACTIVATED CARBON AND METHOD FOR PRODUCING THE SAME Sumitomo Chemical Company, Limited (JP) 2009-08-26 EP disclosed
US-20090103241-A1 Activated carbon prepared by carbonizing and activating a calixarene containing dihydroxybenzene rings; especially calcining at 400 degrees C. or less in the presence of an oxidative gas, calcining at 1500 degrees or less in an inactive gas, and then further calcining at 200-1500 degrees in H2O or CO2 SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-04-23 US disclosed
US-20080094777-A1 Electric double layer capacitor SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-04-24 US disclosed
EP-1905740-A1 ELECTRIC DOUBLE LAYER CAPACITOR Sumitomo Chemical Company, Limited (JP) 2008-04-02 EP disclosed
EP-1876611-A1 ELECTRIC DOUBLE LAYER CAPACITOR Sumitomo Chemical Company, Limited (JP) 2008-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090103241-A1 Activated carbon prepared by carbonizing and activating a calixarene containing dihydroxybenzene rings; especially calcining at 400 degrees C. or less in the presence of an oxidative gas, calcining at 1500 degrees or less in an inactive gas, and then further calcining at 200-1500 degrees in H2O or CO2 CBR1, CYP24A1, CALU HCAR2 292/4885KMT2A 3417/4885CA1 58/4885
US-20240368065-A1 CITRACONIC ACID AND DERIVATIVES THEREOF FOR USE AS A MEDICAMENT HCAR2, ECI1, CYP27A1 HCAR2 1/4885KMT2A 3987/4885CA1 441/4885
US-20190135774-A1 BIOMOLECULE PROCESSING FROM FIXED BIOLOGICAL SAMPLES UNG, POLN, POLB HCAR2 4042/4885KMT2A 1401/4885CA1 3891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.